Diligence memo · auto-generated · as of July 2, 2026
Hapten Sciences, Inc.
Hapten Sciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Hapten Sciences, Inc. operates in Pharmaceuticals, based in MEMPHIS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Hapten Sciences, Inc. has raised $11M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2021-08-10.
Most recent recorded round closed around 2021-08-10.
Valuation (modeled)modeled
Provath models Hapten Sciences, Inc. at approximately $64M (range $2.3M–$373M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.12× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era. Within the normal band (112% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 4.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 55% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: Wiesman Capital & Co., LLC, Curzion Pharmaceuticals, Inc., Providence Therapeutics Inc., EnBiotix, Inc., Metuchen Pharmaceuticals, LLC.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.